LitAlert ~~ GeneLit.com

    • Invitae Launches Study to Explore Impact of Testing Guidelines on Prostate Cancer Patients' Outcomes.
    • [No author given]
    • Precision Oncology News. 2020 Sep 3.
    • DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    • McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM.
    • Int J Gynecol Cancer. 2020 Sep 2:ijgc-2020-001694. doi: 10.1136/ijgc-2020-001694. Epub ahead of print.
    • PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
    • Ricci AD, Rizzo A, Bonucci C, Tober N, Palloni A, Mollica V, Maggio I, Deserti M, Tavolari S, Brandi G.
    • Medicines (Basel). 2020 Aug 31;7(9):E54. doi: 10.3390/medicines7090054.
    • BAP1: Not just a BRCA1-associated protein.
    • Louie BH, Kurzrock R.
    • Cancer Treat Rev. 2020 Aug 20;90:102091. doi: 10.1016/j.ctrv.2020.102091. Epub ahead of print.
    • Review
    • Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
    • Jiang Y, Tian T, Yu C, Zhou W, Yang J, Wang Y, Wen Y, Chen J, Dai J, Jin G, Ma H, Shen H, Hu Z.
    • Biomed Res Int. 2020 Aug 15;2020:6739823. doi: 10.1155/2020/6739823.